On Monday, Spruce Biosciences Inc (NASDAQ: SPRB) was -39.45% drop from the session before settling in for the closing price of $0.13. A 52-week range for SPRB has been $0.11 – $0.87.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -10.26% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 38.24%. With a float of $29.20 million, this company’s outstanding shares have now reached $42.23 million.
In an organization with 21 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -65.04%, operating margin of -1143.37%, and the pretax margin is -1079.94%.
Spruce Biosciences Inc (SPRB) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Spruce Biosciences Inc stocks. The insider ownership of Spruce Biosciences Inc is 30.86%, while institutional ownership is 23.02%.
Spruce Biosciences Inc (SPRB) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 38.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.61% during the next five years compared to -16.93% drop over the previous five years of trading.
Spruce Biosciences Inc (NASDAQ: SPRB) Trading Performance Indicators
You can see what Spruce Biosciences Inc (SPRB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.29, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.67 in one year’s time.
Technical Analysis of Spruce Biosciences Inc (SPRB)
Let’s dig in a bit further. During the last 5-days, its volume was 4.72 million. That was better than the volume of 1.16 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 8.26%. Additionally, its Average True Range was 0.03.
During the past 100 days, Spruce Biosciences Inc’s (SPRB) raw stochastic average was set at 0.14%, which indicates a significant decrease from 0.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 403.77% in the past 14 days, which was higher than the 170.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3012, while its 200-day Moving Average is $0.4247. However, in the short run, Spruce Biosciences Inc’s stock first resistance to watch stands at $0.0964. Second resistance stands at $0.1141. The third major resistance level sits at $0.1234. If the price goes on to break the first support level at $0.0694, it is likely to go to the next support level at $0.0601. The third support level lies at $0.0424 if the price breaches the second support level.
Spruce Biosciences Inc (NASDAQ: SPRB) Key Stats
There are 42,231K outstanding shares of the company, which has a market capitalization of 3.32 million. As of now, sales total 4,910 K while income totals -53,040 K. Its latest quarter income was 700 K while its last quarter net income were -23,560 K.
